BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29563633)

  • 1. Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Murtola TJ; Vihervuori VJ; Lahtela J; Talala K; Taari K; Tammela TL; Auvinen A
    Br J Cancer; 2018 May; 118(9):1248-1254. PubMed ID: 29563633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer.
    Murtola TJ; Sälli SM; Talala K; Taari K; Tammela TLJ; Auvinen A
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):453-460. PubMed ID: 30679762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
    Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.
    Murtola TJ; Kasurinen TVJ; Talala K; Taari K; Tammela TLJ; Auvinen A
    Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):66-76. PubMed ID: 30214034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort.
    Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):483-490. PubMed ID: 30696944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of prostate cancer screening among men using antidiabetic medication.
    Vettenranta A; Murtola TJ; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
    Sci Rep; 2021 Apr; 11(1):7363. PubMed ID: 33795720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort.
    Vihervuori VJ; Talala K; Taari K; Lahtela J; Tammela TLJ; Auvinen A; Raittinen P; Murtola TJ
    Cancer Epidemiol Biomarkers Prev; 2021 May; 30(5):982-989. PubMed ID: 33653815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
    Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
    BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Kinnunen PT; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
    Scand J Urol; 2016 Dec; 50(6):413-419. PubMed ID: 27628763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data.
    Booth N; Rissanen P; Tammela TLJ; Taari K; Talala K; Auvinen A
    Eur J Cancer; 2018 Apr; 93():108-118. PubMed ID: 29501976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
    Pakarainen T; Raitanen J; Talala K; Taari K; Kujala P; Tammela TL; Auvinen A
    Eur Urol; 2016 Sep; 70(3):499-505. PubMed ID: 27210461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midlife metabolic factors and prostate cancer risk in later life.
    Dickerman BA; Torfadottir JE; Valdimarsdottir UA; Wilson KM; Steingrimsdottir L; Aspelund T; Batista JL; Fall K; Giovannucci E; Sigurdardottir LG; Tryggvadottir L; Gudnason V; Markt SC; Mucci LA
    Int J Cancer; 2018 Mar; 142(6):1166-1173. PubMed ID: 29114858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia.
    Nygård LH; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
    Prostate; 2023 Feb; 83(3):246-258. PubMed ID: 36325820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
    Murtola TJ; Karppa EK; Taari K; Talala K; Tammela TL; Auvinen A
    Int J Cancer; 2016 Jun; 138(12):2820-8. PubMed ID: 26804670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCF7L2 type 2 diabetes risk variant, lifestyle factors, and incidence of prostate cancer.
    Drake I; Wallström P; Hindy G; Ericson U; Gullberg B; Bjartell A; Sonestedt E; Orho-Melander M; Wirfält E
    Prostate; 2014 Sep; 74(12):1161-70. PubMed ID: 24961829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.
    Murtola TJ; Peltomaa AI; Talala K; Määttänen L; Taari K; Tammela TLJ; Auvinen A
    Eur Urol Focus; 2017 Apr; 3(2-3):212-220. PubMed ID: 28753762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use.
    Sarre S; Määttänen L; Tammela TL; Auvinen A; Murtola TJ
    Scand J Urol; 2016 Aug; 50(4):267-73. PubMed ID: 26927237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort.
    Bosco C; Garmo H; Hammar N; Walldius G; Jungner I; Malmström H; Holmberg L; Van Hemelrijck M
    BMC Cancer; 2018 Feb; 18(1):205. PubMed ID: 29463235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of retinopathy in people with diabetes, impaired glucose tolerance, and normal glucose tolerance.
    Rajala U; Laakso M; Qiao Q; Keinänen-Kiukaanniemi S
    Diabetes Care; 1998 Oct; 21(10):1664-9. PubMed ID: 9773727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allopurinol and prostate cancer survival in a Finnish population-based cohort.
    Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
    Prostate Cancer Prostatic Dis; 2024 Mar; 27(1):73-80. PubMed ID: 36131010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.